Table 2. Univariate analyses of clinicopathological variables affecting disease-free survival.
Variables | Total (n = 681) |
*Lymph node positive (n = 209) |
*Lymph node negative (n = 472) | ||||||
---|---|---|---|---|---|---|---|---|---|
HR | 95% CI |
p value |
HR | 95% CI |
pvalue | HR | 95% CI | p value | |
Histological grade: 3 vs. 1/2 | 0.823 | 0.541–1.251 | 0.360 | 1.094 | 0.568–2.110 | 0.788 | 0.583 | 0.332–1.022 | 0.059 |
Pathological T stage: 3/4 vs. 1/2 | 3.591 | 1.926–6.695 | <0.001 | 2.129 | 1.009–4.492 | 0.047 | 4.406 | 1.374–14.131 | 0.013 |
Lymph node metastasis: positive vs. negative | 2.709 | 1.867–3.933 | <0.001 | ||||||
Lymphovascular invasion: positive vs. negative | 3.341 | 2.302–4.851 | <0.001 | 2.703 | 1.535–4.760 | 0.001 | 2.343 | 1.231–4.458 | 0.010 |
TILs: 10% increments | 0.982 | 0.974–0.989 | <0.001 | 0.964 | 0.964–0.987 | <0.001 | 0.985 | 0.974–0.995 | 0.005 |
TLSs adjacent to invasive area: moderate to severe vs. no or mild | 0.492 | 0.336–0.720 | <0.001 | 0.354 | 0.210–0.594 | <0.001 | 0.678 | 0.381–1.208 | 0.184 |
MHC-I expression: high vs. low or no | 0.917 | 0.631–1.333 | 0.651 | 0.716 | 0.425–1.206 | 0.210 | 1.170 | 0.679–2.014 | 0.572 |
MHC-II expression: positive vs. negative | 0.713 | 0.460–1.107 | 0.130 | 0.400 | 0.196–0.814 | 0.012 | 1.131 | 0.635–2.013 | 0.677 |
PD-L1 expression: positive vs. negative | 0.487 | 0.198–1.195 | 0.116 | 0.620 | 0.194–1.984 | 0.416 | 0.394 | 0.096–1.620 | 0.197 |
MxA expression: high vs. low | 0.505 | 0.327–0.779 | 0.002 | 0.577 | 0.316–1.054 | 0.074 | 0.479 | 0.256–0.896 | 0.021 |
PKR expression: high vs. low | 0.836 | 0.573–1.219 | 0.352 | 0.793 | 0.468–1.342 | 0.387 | 0.862 | 0.502–1.480 | 0.590 |
CI, confidence interval; HR, hazard ratio; MHC, major histocompatibility complex; MxA, myxovirus resistance gene A; PKR, double-stranded RNA-activated protein kinase; TILs, tumor-infiltrating lymphocytes; TLSs, tertiary lymphoid structures.
*In the columns, lymph node positive and negative refer to patients who have and do not have lymph node metastasis, respectively.